ABG Lab appoints Dr Aamer Khan as Global Key Opinion Leader

U.S. biotech company ABG Lab has welcomed leading aesthetic doctor, regenerative medicine expert, and Harley Street Skin Clinic Clinical Director and Co-Founder Dr Aamer Khan (MB ChB) as its Global Key Opinion Leader. 

 

The partnership brings together two leading lights in the field of regenerative aesthetic medicine and Dr Kahn joins ABG Lab’s growing team of Global Key Opinion Leaders alongside Dr Michael Kane, and Professor Yana Yutskovskaya at an exciting period of global growth for the brand.  

 

Dr Aamer Khan comments:

 

“Regenerative Medicine in aesthetic treatments is the next big growth area in our industry and has been at the heart of our practice since 2006.  Having practiced and studied this subject extensively, I am very excited and honoured to be partnering with such a progressive and forward-thinking brand like ABG Lab who have launched an innovative and ground-breaking concept to the injectable arena.  Their hybrid products are a result of years of ground-breaking research and development, which have culminated in injectables that specifically target and activate cellular regeneration of the skin.

 

Meso-Wharton P199 is a mesotherapy treatment that targets the skin endogenous stem cells, stimulating their proliferation and differentiation, thereby providing the fundamental basis for skin renewal. Meso-Xanthin F199 is an innovative therapy that targets the genes that are responsible for the proteins involved in skin regeneration, these have specific functions of inhibiting chronic inflammatory mediators and restoring damaged DNA, thereby improving the quality of life of the skin cells, making them more durable.

 

These products are safe, well tolerated and produce outstanding results for patients, and I’m looking forward to stepping into the future of our industry together.”